2105 logo

Laekna SHSC:2105 Stock Report

Last Price

HK$10.80

Market Cap

HK$4.0b

7D

19.2%

1Y

-21.7%

Updated

05 Jan, 2025

Data

Company Financials

Laekna, Inc.

SHSC:2105 Stock Report

Market Cap: HK$4.0b

2105 Stock Overview

An investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide. More details

2105 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Revenue grew by 61.4% over the past year

Risk Analysis

Highly volatile share price over the past 3 months compared to the Hong Kong market

Makes less than USD$1m in revenue (CN¥657K)


My Notes

Capture your thoughts, links and company narrative

Laekna, Inc. Competitors

CK Life Sciences Int'l. (Holdings)

SEHK:775

HK$3.9b

Lepu Biopharma

SEHK:2157

HK$4.3b

Jiangsu Recbio Technology

SEHK:2179

HK$4.4b

Beijing Luzhu Biotechnology

SEHK:2480

HK$4.5b

Price History & Performance

Summary of share price highs, lows and changes for Laekna
Historical stock prices
Current Share PriceHK$10.80
52 Week HighHK$17.78
52 Week LowHK$3.15
Beta0
1 Month Change-25.21%
3 Month Change65.14%
1 Year Change-21.74%
3 Year Changen/a
5 Year Changen/a
Change since IPO-8.78%

Recent News & Updates

Recent updates

Shareholder Returns

2105HK BiotechsHK Market
7D19.2%-3.2%-2.1%
1Y-21.7%-7.7%16.9%

Return vs Industry: 2105 underperformed the Hong Kong Biotechs industry which returned -7.7% over the past year.

Return vs Market: 2105 underperformed the Hong Kong Market which returned 16.9% over the past year.

Price Volatility

Is 2105's price volatile compared to industry and market?
2105 volatility
2105 Average Weekly Movement21.8%
Biotechs Industry Average Movement9.4%
Market Average Movement7.9%
10% most volatile stocks in HK Market15.8%
10% least volatile stocks in HK Market3.6%

Stable Share Price: 2105's share price has been volatile over the past 3 months compared to the Hong Kong market.

Volatility Over Time: 2105's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.

About the Company

FoundedEmployeesCEOWebsite
201692Chris Luwww.laekna.com

Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer, and PD-1/PD-L1 drug-resistant solid tumors; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer; LAE005, a ligand-blocking humanized anti-PD-L1 IgG4 antibody for the treatment of triple-negative breast cancer; and LAE102, a monoclonal antibody against ActRIIA to treat obesity. It also develops LAE109, LAE111, LAE112, LAE113, LAE117, LAE118, LAE119, and LAE120 for the treatment of cancer; LAE103 and LAE123 to treat muscle atrophy diseases; LAE104 and LAE105 for the treatment of liver fibrosis; and LAE106 to treat fibrosis.

Laekna, Inc. Fundamentals Summary

How do Laekna's earnings and revenue compare to its market cap?
2105 fundamental statistics
Market capHK$4.04b
Earnings (TTM)-HK$314.05m
Revenue (TTM)HK$698.16k

5,780x

P/S Ratio

-12.8x

P/E Ratio

Is 2105 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2105 income statement (TTM)
RevenueCN¥657.00k
Cost of RevenueCN¥0
Gross ProfitCN¥657.00k
Other ExpensesCN¥296.19m
Earnings-CN¥295.53m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.79
Gross Margin100.00%
Net Profit Margin-44,982.50%
Debt/Equity Ratio8.4%

How did 2105 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 05:37
End of Day Share Price 2025/01/03 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Laekna, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution